Recombinant Anti-Monkeypox L1 Antibody (Clone: MPXV-26)
Roll over image to zoom in
Shipping Info:
For estimated delivery dates, please contact us at support@abeomics.com
| Amount : | 100 µg (1mg/mL) |
| Isotype : | Human IgG1λ |
| Purification : | ≥95% monomer by analytical SEC |
| Content : | 1.0 mg/ml. Formulation: This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. |
| Storage condition : | Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -70°C. Avoid Repeated Freeze Thaw Cycles. |
| Alternative Name : | MPXV |
| Immunogen Information : | MPXV-26 was generated from peripheral blood mononuclear cells obtained from donors who had recovered from naturally-occurring MPXV infection |
Reactivity Species: Vaccinia,Variola,Cowpox,Monkeypox,Virus
Expression Host: HEK-293
Endotoxin Level: ≤ 1.0 EU/mg as determined by the LAL method
Specificity: MPXV-26 is reactive against L1, an MV surface protein. Complementary screening approaches were used to identify orthopoxvirus-specific mAbs to MPXV, cowpox virus (CPXV), variola virus (VARV), and vaccinia virus (VACV). MPXV-26 is reactive to VACV antigen, CPXV lysate, VARV antigen and lysate, but not MPXV lysate. MPXV-26 binds to VACV and VARV purified antigens and CPXV virus-infected cell lysate but not VACV and MPXV cell lysates. MPXV-26 neutralizes VACV MV and MV plus complement (MV+C’), CPXV MV and MV+C’, and weakly neutralizes MPXV MV and MV+C’. With cocktail of anti-monkeypox mAbs, neutralization and cross-neutralization are more efficient than in individual assays5. These mAb mixes also provide protection against VACV in mice. While not completely protective on its own, MPXV-26 induces delayed morbidity and mortality in mice, and mixes that exclude MPXV-26 are less effective prophylactics.
Endotoxin Level: ≤ 1.0 EU/mg as determined by the LAL method
Specificity: MPXV-26 is reactive against L1, an MV surface protein. Complementary screening approaches were used to identify orthopoxvirus-specific mAbs to MPXV, cowpox virus (CPXV), variola virus (VARV), and vaccinia virus (VACV). MPXV-26 is reactive to VACV antigen, CPXV lysate, VARV antigen and lysate, but not MPXV lysate. MPXV-26 binds to VACV and VARV purified antigens and CPXV virus-infected cell lysate but not VACV and MPXV cell lysates. MPXV-26 neutralizes VACV MV and MV plus complement (MV+C’), CPXV MV and MV+C’, and weakly neutralizes MPXV MV and MV+C’. With cocktail of anti-monkeypox mAbs, neutralization and cross-neutralization are more efficient than in individual assays5. These mAb mixes also provide protection against VACV in mice. While not completely protective on its own, MPXV-26 induces delayed morbidity and mortality in mice, and mixes that exclude MPXV-26 are less effective prophylactics.
|
There are currently no product reviews
|
